GSK presents positive pivotal data on its MenABCWY combo vaccine

UK pharma major GSK (LSE: GSK) saw its shares gain 2.3% to 1,478 pence today, after it presented preliminary positive results from the Phase III trial evaluating the immunological vaccine effectiveness and safety of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years.

The preliminary data were disclosed at the 41st Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) taking place in Lisbon, Portugal.

The vaccine candidate demonstrated non-inferiority in primary endpoints for five Neisseria meningitidis serogroups (A, B, C, W, and Y) compared to two doses of GSK’s Bexsero (meningococcal group B vaccine) and one dose of Menveo (meningococcal group A, C, W-135, and Y conjugate vaccine) in 10–25-year-olds. In addition, the vaccine candidate was generally well tolerated, with a safety profile consistent with Bexsero and Menveo.